Dana Lawson ’95 and Kim Diamond ’95


Dana Lawson ’95 and Kim Diamond ’95 both were involved in the development of the first FDA-approved drug to treat a rare type of cancer; Lawson as a patient advocate and Diamond as a biotech company vice president. Forbes reports on how a promising first trial eventually led researchers, healthcare providers, patient advocates, and investors to produce an effective treatment for desmoid tumors, which affect nerve and muscle tissues.

Learn More.

Source: Forbes